Proliferative Vitreoretinopathy in Rhegmatogenous Retinal DetachmentNCT07774182
Intravitreal Triamcinolone and Biomarkers in Rhegmatogenous Retinal Detachment
A study testing Standard Vitrectomy and Triamcinolone acetonide (TA) in people with Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment, run by Anggun Rama Yudantha at 1 site in Indonesia.
Trial summary
This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
- What is being tested?
- Standard Vitrectomy and Triamcinolone acetonide (TA)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteIndonesia
- Study dates
- 6 May 2025to 18 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR) grade B or C.
- No previous history of rhegmatogenous retinal detachment.
- No requirement for surgical intervention other than treatment for RRD.
- Willingness to participate in all study procedures and provide written informed consent.
Who cannot join
- RRD with vitreous opacity precluding adequate fundus examination.
- RRD caused by a giant retinal tear.
- History of cataract surgery within the previous 3 months.
- RRD associated with other ocular comorbidities.
- Systemic disease that precludes vitrectomy.
- History of ocular hypertension or glaucoma.
- RRD with a cloudy lens requiring cataract surgery.
Trial locations and contacts
1 site in 1 country.
Indonesia1 site
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta
Jakarta, DKI Jakarta
About this study
Official title: Effect of Intravitreal Triamcinolone Acetonide on TGF-β2, TGF-β3, and Matrix Metalloproteinase Levels in Patients With Rhegmatogenous Retinal Detachment: A Study of Aqueous Humor and Vitreous Biomarkers
This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR). Participants are assigned to either an intervention group receiving a 2-mg intravitreal injection of TA 5-7 days before vitrectomy or a control group receiving standard surgical treatment. The study evaluates TGF-β2, TGF-β3, MMP-2, and MMP-9 levels in aqueous humor and vitreous, macrophage cell counts and inflammatory activity in vitreous, subretinal fluid optical density assessed by optical coherence tomography, and vessel diameter index assessed by optical coherence tomography angiography after surgery.
Read the detailed description
Rhegmatogenous retinal detachment (RRD) complicated by proliferative vitreoretinopathy (PVR) is associated with inflammatory and fibrotic processes that may contribute to retinal structural changes and surgical failure. Transforming growth factor beta (TGF-β) and matrix metalloproteinases (MMPs) are among the mediators involved in these processes, while macrophages may contribute to the inflammatory response associated with PVR.
This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with RRD and PVR. Eligible participants are allocated to receive either a 2-mg intravitreal injection of TA 5-7 days before vitrectomy or standard surgical treatment without preoperative TA.
The study evaluates TGF-β2, TGF-β3, MMP-2, and MMP-9 concentrations in aqueous humor and vitreous samples, as well as vitreous macrophage cell counts and inflammatory activity. Subretinal fluid optical density and postoperative vessel diameter index are also evaluated to assess retinal structural and vascular parameters.
The study aims to determine whether preoperative intravitreal TA is associated with changes in inflammatory and growth factor profiles, macrophage-related parameters, subretinal fluid optical density, and postoperative vascular parameters in patients with RRD and PVR.
- Being tested
- Standard Vitrectomy, Triamcinolone acetonide (TA)
- Keywords
- Rhegmatogenous retinal detachment, Proliferative vitreoretinopathy, Intravitreal triamcinolone acetonide, TGF-beta, Matrix metalloproteinases, MMP-2, MMP-9, Macrophages, Vitreous biomarkers, Aqueous humor biomarkers
- Medical subject headings
- Vitreoretinopathy, Proliferative, Camurati-Engelmann Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard VitrectomyProcedure or surgery
Participants underwent standard surgical treatment for rhegmatogenous retinal detachment with proliferative vitreoretinopathy without preoperative intravitreal triamcinolone acetonide.
Triamcinolone acetonide (TA)Drug
Triamcinolone acetonide 2 mg was administered by intravitreal injection 5-7 days before vitrectomy.
| Study group | Role | What they receive |
|---|---|---|
| Control | Active comparator | Participants received standard surgical treatment for rhegmatogenous retinal detachment with proliferative vitreoretinopathy without preoperative intravitreal triamcinolone acetonide. Receives: Procedure: Standard Vitrectomy |
| Intravitreal Triamcinolone Acetonide | Experimental | Participants received a 2-mg intravitreal injection of triamcinolone acetonide 5-7 days before vitrectomy for rhegmatogenous retinal detachment with proliferative vitreoretinopathy. Receives: Procedure: Standard Vitrectomy; Drug: Triamcinolone acetonide (TA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Aqueous Humor TGF-β2, TGF-β3, MMP-2, and MMP-9 Levels
Change in aqueous humor concentrations of TGF-β2, TGF-β3, MMP-2, and MMP-9 before and after preoperative intravitreal administration of 2 mg triamcinolone acetonide in the intervention group. Biomarker concentrations are measured using a multiplex assay and expressed in pg/mL.
Measured: From before intravitreal triamcinolone acetonide administration to 5-7 days after administration, immediately before vitrectomy.
Secondary outcomes (4)
Change in Subretinal Fluid Optical Density Following Intravitreal Triamcinolone Acetonide
Change in optical density of subretinal fluid before and after preoperative intravitreal administration of 2 mg triamcinolone acetonide in the intervention group. Optical density is assessed using optical coherence tomography (OCT) images and image analysis.
Measured: From before intravitreal triamcinolone acetonide administration to 5-7 days after administration, immediately before vitrectomy.
Vitreous TGF-β2, TGF-β3, MMP-2, and MMP-9 Levels
Concentrations of TGF-β2, TGF-β3, MMP-2, and MMP-9 in vitreous samples collected during vitrectomy, comparing participants who received preoperative intravitreal triamcinolone acetonide with control participants who received standard surgical treatment without preoperative triamcinolone acetonide. Biomarker concentrations are measured using a multiplex assay and expressed in pg/mL.
Measured: At the time of vitrectomy; 5-7 days after intravitreal triamcinolone acetonide administration in the intervention group.
Vitreous Macrophage Count and Inflammatory Activity
Macrophage populations and inflammatory activity in vitreous samples collected during vitrectomy are assessed using flow cytometry. Macrophage populations include total macrophages (CD68⁺), M0 macrophages (CD68⁺CD80-CD206-), M1 macrophages (CD68⁺CD80⁺), and M2 macrophages (CD68⁺CD206⁺). Macrophage inflammatory activity is assessed by the percentage of NF-κB-positive cells (NF-κB, %). Outcomes are compared between participants who received preoperative intravitreal triamcinolone acetonide and control participants who received standard surgical treatment without preoperative intravitreal triamcinolone acetonide.
Measured: At the time of vitrectomy.
Vessel Diameter Index After Vitrectomy
Vessel diameter index (VDI) is measured using optical coherence tomography angiography (OCTA) after vitrectomy. VDI is calculated by dividing vascular density by vascular length density. VDI is compared between participants who received preoperative intravitreal triamcinolone acetonide and control participants who received standard surgical treatment without preoperative triamcinolone acetonide.
Measured: Postoperative weeks 1, 2, and 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2026
- Study start6 May 2025
- Primary completion18 Feb 2026
- Study completion18 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Proliferative Vitreoretinopathy in Rhegmatogenous Retinal DetachmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anggun Rama Yudantha
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Anggun Rama Yudantha, Universitas Indonesia
- Investigators
- Anggun Rama Yudantha, Sp.M(K), Principal investigator, Cipto Mangunkusumo Hospital / Faculty of Medicine, Universitas Indonesia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07774182
- Sponsor's protocol ID
- KET-1409/UN2.F1/ETIK/PPM.OO.02
- Status last verified
- Aug 2026
- First submitted
- 15 Aug 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Protection of patient data and privacy
Publications
Leshno A, Barak A, Loewenstein A, Weinberg A, Neudorfer M. Optical Density of Subretinal Fluid in Retinal Detachment. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5432-8. doi: 10.1167/iovs.15-16952.
PubMed 26284548Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E. Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol. 2011 Jun;89(4):339-45. doi: 10.1111/j.1755-3768.2009.01701.x. Epub 2009 Sep 18.
PubMed 19764916Webster L, Chignell AH, Limb GA. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res. 1999 Jan;68(1):91-8. doi: 10.1006/exer.1998.0585.
PubMed 9986746Caban M, Owczarek K, Lewandowska U. The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms. Int J Mol Sci. 2022 Apr 12;23(8):4256. doi: 10.3390/ijms23084256.
PubMed 35457074Hsiao CC, Chang YC, Hsiao YT, Chen PH, Hsieh MC, Wu WC, Kao YH. Triamcinolone acetonide modulates TGF-beta2-induced angiogenic and tissue-remodeling effects in cultured human retinal pigment epithelial cells. Mol Med Rep. 2021 Nov;24(5):802. doi: 10.3892/mmr.2021.12442. Epub 2021 Sep 15.
PubMed 34523693Kunikata H, Yasuda M, Aizawa N, Tanaka Y, Abe T, Nakazawa T. Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide. Am J Ophthalmol. 2013 Jun;155(6):1028-1037.e1. doi: 10.1016/j.ajo.2013.01.013. Epub 2013 Mar 12.
PubMed 23490191Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2009 Mar;127(3):275-81. doi: 10.1001/archophthalmol.2008.602.
PubMed 19273790Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000 Sep;84(9):1064-7. doi: 10.1136/bjo.84.9.1064.
PubMed 10966969Idrees S, Sridhar J, Kuriyan AE. Proliferative Vitreoretinopathy: A Review. Int Ophthalmol Clin. 2019 Winter;59(1):221-240. doi: 10.1097/IIO.0000000000000258.
PubMed 30585928Guber J, Bentivoglio M, Valmaggia C, Lang C, Guber I. Predictive Risk Factors for Retinal Redetachment Following Uncomplicated Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment. J Clin Med. 2020 Dec 14;9(12):4037. doi: 10.3390/jcm9124037.
PubMed 33327511Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991 Aug 15;112(2):159-65. doi: 10.1016/s0002-9394(14)76695-4.
PubMed 1867299
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Intravitreal Triamcinolone Acetonide on TGF-β2, TGF-β3, and Matrix Metalloproteinase Levels in Patients With Rhegmatogenous Retinal Detachment: A Study of Aqueous Humor and Vitreous Biomarkers
- ClinicalTrials.gov ID
- NCT07774182
- Acronym / sponsor ID
- KET-1409/UN2.F1/ETIK/PPM.OO.02
- Keywords
- Rhegmatogenous retinal detachment, Proliferative vitreoretinopathy, Intravitreal triamcinolone acetonide, TGF-beta, Matrix metalloproteinases, MMP-2, MMP-9, Macrophages
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Anggun Rama YudanthaUniversity, hospital or other
- Study start
- 6 May 2025 (actual)
- Primary completion
- 18 Feb 2026 (actual)
- Study completion
- 18 Mar 2026 (actual)
- First posted
- 19 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR). Participants are assigned to either an intervention group receiving a 2-mg intravitreal injection of TA 5-7 days before vitrectomy or a control group receiving standard surgical treatment. The study evaluates TGF-β2, TGF-β3, MMP-2, and MMP-9 levels in aqueous humor and vitreous, macrophage cell counts and inflammatory activity in vitreous, subretinal fluid optical density assessed by optical coherence tomography, and vessel diameter index assessed by optical coherence tomography angiography after surgery.
Detailed description
Rhegmatogenous retinal detachment (RRD) complicated by proliferative vitreoretinopathy (PVR) is associated with inflammatory and fibrotic processes that may contribute to retinal structural changes and surgical failure. Transforming growth factor beta (TGF-β) and matrix metalloproteinases (MMPs) are among the mediators involved in these processes, while macrophages may contribute to the inflammatory response associated with PVR.
This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with RRD and PVR. Eligible participants are allocated to receive either a 2-mg intravitreal injection of TA 5-7 days before vitrectomy or standard surgical treatment without preoperative TA.
The study evaluates TGF-β2, TGF-β3, MMP-2, and MMP-9 concentrations in aqueous humor and vitreous samples, as well as vitreous macrophage cell counts and inflammatory activity. Subretinal fluid optical density and postoperative vessel diameter index are also evaluated to assess retinal structural and vascular parameters.
The study aims to determine whether preoperative intravitreal TA is associated with changes in inflammatory and growth factor profiles, macrophage-related parameters, subretinal fluid optical density, and postoperative vascular parameters in patients with RRD and PVR.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | Active comparator | Procedure: Standard VitrectomyParticipants received standard surgical treatment for rhegmatogenous retinal detachment with proliferative vitreoretinopathy without preoperative intravitreal triamcinolone acetonide. |
| Intravitreal Triamcinolone Acetonide | Experimental | Procedure: Standard Vitrectomy, Drug: Triamcinolone acetonide (TA)Participants received a 2-mg intravitreal injection of triamcinolone acetonide 5-7 days before vitrectomy for rhegmatogenous retinal detachment with proliferative vitreoretinopathy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults aged 18 years or older with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR) grade B or C.
- No previous history of rhegmatogenous retinal detachment.
- No requirement for surgical intervention other than treatment for RRD.
- Willingness to participate in all study procedures and provide written informed consent.
Key exclusion criteria (7 listed)
- RRD with vitreous opacity precluding adequate fundus examination.
- RRD caused by a giant retinal tear.
- History of cataract surgery within the previous 3 months.
- RRD associated with other ocular comorbidities.
- Systemic disease that precludes vitrectomy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard VitrectomyParticipants underwent standard surgical treatment for rhegmatogenous retinal detachment with proliferative vitreoretinopathy without preoperative intravitreal triamcinolone acetonide. | Procedure or surgery | Control, Intravitreal Triamcinolone Acetonide |
| Triamcinolone acetonide (TA)Triamcinolone acetonide 2 mg was administered by intravitreal injection 5-7 days before vitrectomy. | Drug | Intravitreal Triamcinolone Acetonide |
Primary outcome
Change in Aqueous Humor TGF-β2, TGF-β3, MMP-2, and MMP-9 Levels
Time frame: From before intravitreal triamcinolone acetonide administration to 5-7 days after administration, immediately before vitrectomy.
Change in aqueous humor concentrations of TGF-β2, TGF-β3, MMP-2, and MMP-9 before and after preoperative intravitreal administration of 2 mg triamcinolone acetonide in the intervention group. Biomarker concentrations are measured using a multiplex assay and expressed in pg/mL.
4 secondary outcomes
Change in Subretinal Fluid Optical Density Following Intravitreal Triamcinolone Acetonide
Time frame: From before intravitreal triamcinolone acetonide administration to 5-7 days after administration, immediately before vitrectomy.
Vitreous TGF-β2, TGF-β3, MMP-2, and MMP-9 Levels
Time frame: At the time of vitrectomy; 5-7 days after intravitreal triamcinolone acetonide administration in the intervention group.
Vitreous Macrophage Count and Inflammatory Activity
Time frame: At the time of vitrectomy.
Vessel Diameter Index After Vitrectomy
Time frame: Postoperative weeks 1, 2, and 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Background: PubMed 26284548Leshno A, Barak A, Loewenstein A, Weinberg A, Neudorfer M. Optical Density of Subretinal Fluid in Retinal Detachment. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5432-8. doi: 10.1167/iovs.15-16952.
- Background: PubMed 19764916Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E. Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol. 2011 Jun;89(4):339-45. doi: 10.1111/j.1755-3768.2009.01701.x. Epub 2009 Sep 18.
- Background: PubMed 9986746Webster L, Chignell AH, Limb GA. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res. 1999 Jan;68(1):91-8. doi: 10.1006/exer.1998.0585.
- Background: PubMed 35457074Caban M, Owczarek K, Lewandowska U. The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms. Int J Mol Sci. 2022 Apr 12;23(8):4256. doi: 10.3390/ijms23084256.
- Background: PubMed 34523693Hsiao CC, Chang YC, Hsiao YT, Chen PH, Hsieh MC, Wu WC, Kao YH. Triamcinolone acetonide modulates TGF-beta2-induced angiogenic and tissue-remodeling effects in cultured human retinal pigment epithelial cells. Mol Med Rep. 2021 Nov;24(5):802. doi: 10.3892/mmr.2021.12442. Epub 2021 Sep 15.
- Background: PubMed 23490191Kunikata H, Yasuda M, Aizawa N, Tanaka Y, Abe T, Nakazawa T. Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide. Am J Ophthalmol. 2013 Jun;155(6):1028-1037.e1. doi: 10.1016/j.ajo.2013.01.013. Epub 2013 Mar 12.
- Background: PubMed 19273790Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2009 Mar;127(3):275-81. doi: 10.1001/archophthalmol.2008.602.
- Background: PubMed 10966969Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000 Sep;84(9):1064-7. doi: 10.1136/bjo.84.9.1064.
- Background: PubMed 30585928Idrees S, Sridhar J, Kuriyan AE. Proliferative Vitreoretinopathy: A Review. Int Ophthalmol Clin. 2019 Winter;59(1):221-240. doi: 10.1097/IIO.0000000000000258.
- Background: PubMed 33327511Guber J, Bentivoglio M, Valmaggia C, Lang C, Guber I. Predictive Risk Factors for Retinal Redetachment Following Uncomplicated Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment. J Clin Med. 2020 Dec 14;9(12):4037. doi: 10.3390/jcm9124037.
- Background: PubMed 1867299Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991 Aug 15;112(2):159-65. doi: 10.1016/s0002-9394(14)76695-4.
- Individual participant dataSharing planned: No. Protection of patient data and privacy
Related trials for Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
RecruitingPhase 2
Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
RecruitingPhase 1/2
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Not yet recruitingObservational study
Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment
Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
Not yet recruitingPhase 2
Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment
Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
RecruitingPhase 2
Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anggun Rama Yudantha, Sp.M(K) principal investigator
Cipto Mangunkusumo Hospital / Faculty of Medicine, Universitas Indonesia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standard Vitrectomy and Triamcinolone acetonide (TA) in people with Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment, run by Anggun Rama Yudantha at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Aqueous Humor TGF-β2, TGF-β3, MMP-2, and MMP-9 Levels (time frame: From before intravitreal triamcinolone acetonide administration to 5-7 days after administration, immediately before vitrectomy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07774182, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.